Skip to main content
. 2024 Aug 27;14:1323176. doi: 10.3389/fonc.2024.1323176

Figure 3.

Figure 3

Overview of surveillance for tumor screening and recommendations for their management. Adapted from Carton et al., 2023 (75). CT, computed tomography; 18FDG PET MRI, 18F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging; 18FDG PET-CT, 18F-fluorodeoxyglucose positron emission tomography-computed tomography; MEK, mitogen-activated protein kinase; MPNST, Malignant peripheral nerve sheath tumor; MRI, magnetic resonance imaging; mTOR, mammalian target of rapamycin; NF1, neurofibromatosis type 1; OCT, optic coherence tomography; PN, plexiform neurofibromas. *For high-grade gliomas, a detailed family history and genetic testing (whole exome sequencing) need to be taken if not already done.